USIA Fellow Dr. Aubrey de Grey


Dr. Aubrey de Grey is an Honorary/Advisory Scientist for Biomedical Gerontologist of the United Sigma Intelligence Association.

Dr. Aubrey de Grey is a biomedical gerontologist based in Cambridge, UK and Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) charity dedicated to combating the aging process. He is also Editor-in-Chief of Rejuvenation Research, the world highest-impact peer-reviewed journal focused on intervention in aging.

He received his BA and Ph.D. from the University of Cambridge in 1985 and 2000 respectively. His original field was computer science, and he did research in the private sector for six years in the area of software verification before switching to biogerontology in the mid-1990s. His research interests encompass the characterization of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

He has developed a possibly comprehensive plan for such repair, termed Strategies for Engineered Negligible Senescence (SENS), which breaks aging down into seven major classes of damage and identifies detailed approaches to addressing each one. A key aspect of SENS is that it can potentially extend healthy lifespan without limit, even though these repair processes will probably never be perfect, as the repair only needs to approach perfection rapidly enough to keep the overall level of damage below pathogenic levels. Dr. de Grey has termed this required rate of improvement of repair therapies longevity escape velocity.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

“Our goals could be described in terms of science and also in terms of community. In terms of science, the goals are clearly to pursue the development of medicines that would turn back the clock of aging, to actually develop medicines that will genuinely rejuvenate the body by restoring the molecular and cellular structure and composition of the body to something like how it is in early adulthood. However, I never felt that this was something that SENS Research Foundation or any organization that I would be leading would do on its own. We are the pioneers; we are the engine room of all of this. The credibility of the overall goal has become increasingly clear, and more and more people are getting involved. And that might cause SRF to grow but it also causes other organizations and other individuals to come along into the mission and get involved in their own ways including in the private sector. Even at the start, I used to say that my basic goal was to become unnecessary.”

*Reference from SENS Research Foundation, and Singularity University.